BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 17646043)

  • 1. Adenosine A2A receptors and basal ganglia physiology.
    Schiffmann SN; Fisone G; Moresco R; Cunha RA; Ferré S
    Prog Neurobiol; 2007 Dec; 83(5):277-92. PubMed ID: 17646043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Dual Role Hypothesis of the Cortico-Basal-Ganglia Pathways: Opponency and Temporal Difference Through Dopamine and Adenosine.
    Morita K; Kawaguchi Y
    Front Neural Circuits; 2018; 12():111. PubMed ID: 30687019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function.
    Rosin DL; Hettinger BD; Lee A; Linden J
    Neurology; 2003 Dec; 61(11 Suppl 6):S12-8. PubMed ID: 14663003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenosine A2A-D2 receptor-receptor interactions in putative heteromers in the regulation of the striato-pallidal gaba pathway: possible relevance for parkinson's disease and its treatment.
    Beggiato S; Antonelli T; Tomasini MC; Borelli AC; Agnati LF; Tanganelli S; Fuxe K; Ferraro L
    Curr Protein Pept Sci; 2014; 15(7):673-80. PubMed ID: 25175458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
    Morin N; Di Paolo T
    Int Rev Neurobiol; 2014; 119():151-67. PubMed ID: 25175965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia.
    Fuxe K; Ferré S; Zoli M; Agnati LF
    Brain Res Brain Res Rev; 1998 May; 26(2-3):258-73. PubMed ID: 9651540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists.
    Mori A; Shindou T
    Neurology; 2003 Dec; 61(11 Suppl 6):S44-8. PubMed ID: 14663009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia.
    Kase H
    Biosci Biotechnol Biochem; 2001 Jul; 65(7):1447-57. PubMed ID: 11515525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function.
    Fuxe K; Ferré S; Genedani S; Franco R; Agnati LF
    Physiol Behav; 2007 Sep; 92(1-2):210-7. PubMed ID: 17572452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.
    Morelli M; Di Paolo T; Wardas J; Calon F; Xiao D; Schwarzschild MA
    Prog Neurobiol; 2007 Dec; 83(5):293-309. PubMed ID: 17826884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal adenosine-cannabinoid receptor interactions in rats over-expressing adenosine A2A receptors.
    Chiodi V; Ferrante A; Ferraro L; Potenza RL; Armida M; Beggiato S; Pèzzola A; Bader M; Fuxe K; Popoli P; Domenici MR
    J Neurochem; 2016 Mar; 136(5):907-17. PubMed ID: 26526685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease.
    Fuxe K; Agnati LF; Jacobsen K; Hillion J; Canals M; Torvinen M; Tinner-Staines B; Staines W; Rosin D; Terasmaa A; Popoli P; Leo G; Vergoni V; Lluis C; Ciruela F; Franco R; Ferré S
    Neurology; 2003 Dec; 61(11 Suppl 6):S19-23. PubMed ID: 14663004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic deletion of GPR52 enhances the locomotor-stimulating effect of an adenosine A
    Nishiyama K; Suzuki H; Maruyama M; Yoshihara T; Ohta H
    Brain Res; 2017 Sep; 1670():24-31. PubMed ID: 28583861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors.
    Ferré S; Quiroz C; Woods AS; Cunha R; Popoli P; Ciruela F; Lluis C; Franco R; Azdad K; Schiffmann SN
    Curr Pharm Des; 2008; 14(15):1468-74. PubMed ID: 18537670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boolean analysis shows a high proportion of dopamine D
    Rivas-Santisteban R; Rico AJ; Muñoz A; Rodríguez-Pérez AI; Reyes-Resina I; Navarro G; Labandeira-García JL; Lanciego JL; Franco R
    Neurobiol Dis; 2023 Nov; 188():106341. PubMed ID: 37918757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric Interactions between Adenosine A
    Prasad K; de Vries EFJ; Elsinga PH; Dierckx RAJO; van Waarde A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opposing actions of adenosine A2a and dopamine D2 receptor activation on GABA release in the basal ganglia: evidence for an A2a/D2 receptor interaction in globus pallidus.
    Dayne Mayfield R; Larson G; Orona RA; Zahniser NR
    Synapse; 1996 Feb; 22(2):132-8. PubMed ID: 8787129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors.
    Díaz-Cabiale Z; Vivó M; Del Arco A; O'Connor WT; Harte MK; Müller CE; Martínez E; Popoli P; Fuxe K; Ferré S
    Neurosci Lett; 2002 May; 324(2):154-8. PubMed ID: 11988350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purinergic Receptors in Basal Ganglia Diseases: Shared Molecular Mechanisms between Huntington's and Parkinson's Disease.
    Glaser T; Andrejew R; Oliveira-Giacomelli Á; Ribeiro DE; Bonfim Marques L; Ye Q; Ren WJ; Semyanov A; Illes P; Tang Y; Ulrich H
    Neurosci Bull; 2020 Nov; 36(11):1299-1314. PubMed ID: 33026587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Striatal astrocytic A2A-D2 receptor-receptor interactions and their role in neuropsychiatric disorders.
    Cervetto C; Maura G; Guidolin D; Amato S; Ceccoli C; Agnati LF; Marcoli M
    Neuropharmacology; 2023 Oct; 237():109636. PubMed ID: 37321323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.